Although the researchers did not focus on MASLD, their analysis highlights the pleiotropic effects of RANKL in metabolic pathways and again suggests that RROa could represent a novel pharmacological target in treating disorders across the metabolic syndrome spectrum. This evidence concerns the gene TNFSF11 and metabolic syndrome.